gvhd

(E/Z)-IT-603 is a cell-permeable c-Rel inhibitor (IC50: 3μM) that directly and reversibly binds to c-Rel, altering its conformation and inhibiting its DNA binding and transcriptional activity.

AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).

AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).

Preimplantation Factor (PIF-1) exhibits potential activity against graft-versus-host disease (GVHD).

CW8001 is a covalent Exportin-1 (XPO1) inhibitor with an EC50 value of 1 nM for inhibiting T cell activation. It prevents the nuclear localization of NFAT transcription factors, thereby suppressing the expression of inflammatory cytokines like IL-2. CW8001 shows potential for research in T cell-driven immune diseases such as graft-versus-host disease (GVHD).

CS12192 is a compound that improves survival and increases body weight and has potential for graft-versus-host disease (GVHD) research.

Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that specifically binds to human CD162 (PSGL-1). this binding leads to the downregulation and apoptosis of activated T cells, a mechanism currently in clinical development for the treatment of steroid-refractory acute graft-versus-host disease (GVHD), psoriasis, psoriatic arthritis, and ulcerative colitis.

Asunercept (APG101; CAN008), a soluble CD95-Fc fusion protein, selectively targets and binds to CD95L, effectively disrupting CD95/CD95L signaling. It is utilized in research for treating glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) [1] [2] [3].

Olendalizumab is a humanized monoclonal antibody targeting complement component C5a. Olendalizumab blocks the interaction between C5a and receptor C5aR(CD88) by specifically binding C5a, thus inhibiting C5a-mediated inflammatory reaction and chemotaxis and activation of neutrophils. Olendalizumab is used for inflammatory diseases mediated by complement, such as sepsis, graft-versus-host disease (GVHD) and viral infection (such as COVID-19).

Dafsolimab (SPV-T3a), an IgG2a murine monoclonal antibody (anti-CD3), induces cell death by modulating and activating the CD3/T cell receptor complex and is utilized in research pertaining to graft-versus-host disease (GVHD) [1].

XY-52 (Compound 32), an ST2 (Stimulation-2) inhibitor, exhibits IC50 values of 5.68 μM and 4.59 μM in the AlphaLISA and HEK-Blue assays, respectively. It promotes proinflammatory T-cell proliferation and diminishes plasma sST2 and IFNγ biomarkers in a graft versus host disease (GVHD) mouse model [1].

VLHDDLLEA, a peptide extractable from the HLA-A*0201 MHC complex, is identifiable by HLA-A*0201-restricted cytotoxic T cells (CTLs). It serves as a research tool in studies of graft versus host disease (GvHD) [1].

Gavilimomab (ABX-CBL) is a murine-derived IgM monoclonal antibody against CD147 antigen used in immunosuppressive biologic treatments for glucocorticoid-resistant graft-versus-host disease (GVHD).

Zharp1-211 is a selective and potent RIPK3 inhibitor that significantly reduces the expression of JAK/ stat1-mediated chemokines and MHC class II molecules in IECs, restores intestinal homeostasis, and inhibits graft-versus-host disease (GVHD) for gastrointestinal inflammation.

Anti-Mouse OX40L/CD134L Antibody (RM134L) is a monoclonal antibody against mouse OX40L/CD134L that can attenuate immune responses by blocking the OX40/OX40L signaling pathway and inhibit plasma cell differentiation and antibody secretion.In addition, Anti-Mouse OX40L/CD134L Antibody (RM134L) can effectively prolong the survival time of cellular transplants by acting on CD4+ T cells.This antibody is suitable for studies related to inflammation and cancer, including graft-versus-host disease (GVHD), allergic reactions, lupus nephritis, and hepatocellular carcinoma (HCC) .

Anti-CD83 Antibody is a humanized monoclonal antibody targeting CD83, a marker for mature dendritic cells (DCs). It interferes with immunomodulatory functions by specifically binding to the extracellular domain of CD83. The antibody works by depleting CD83+ cells or blocking costimulatory signals, serving as an advanced compound tool for studying immune tolerance induction, graft-versus-host disease (GvHD) suppression, and autoimmune disease treatment.

Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic antibody targeting CD28 that can effectively induce T cell activation and has broad research value in fields such as neurological diseases, inflammation, immunology, and oncology. It can be applied to studies on the mechanisms and interventions of Parkinson's disease (PD), arthritis, and graft-versus-host disease (GVHD).

NecroX-7 (LC-280126) is a potent free radical scavenger and HMGB1 (high-mobility group box 1) inhibitor. It serves as an antidote to acetaminophen toxicity and exerts a protective effect by preventing HMGB1 release in ischemia/reperfusion injury. Additionally, NecroX-7 inhibits HMGB1-induced release of TNF and IL-6 and the expression of TLR-4 and receptor for advanced glycation end products. This compound may be used for graft-versus-host disease (GVHD) research [1].